Sabinsa’s Curcumin C3 Used in New Study on NAFLD

595

East Windsor, NJ—Sabinsa’s Curcumin C3 Complex was used in a new published study on Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver condition for which no approved pharmaceutical treatments exist, according to a press release.

NAFLD is a spectrum of disorders ranging from steatosis to cirrhosis of the liver. It is commonly associated with metabolic syndrome and cardiovascular diseases.

Related: Sami-Sabinsa Group Honored with Multiple Awards
Sabinsa Founder Publishes New Book on Curcuminoids
Study: Curcumin, Resveratrol Possible Anti-Cancer Compounds

The paper was published in the Journal of Cellular Biochemistry. 70 subjects with NAFLD were randomized to either Curcumin C3 Complex with BioPerine or a placebo for 12 weeks. Supplementation significantly reduced the hematocrit, erythrocyte sedimentation rate, and the serum concentrations of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, cholesterol, and hemoglobin, and increased total iron-binding capacity. The supplement “significantly improved NAFLD severity (p<0.001), which was statistically different compared with the placebo group.”

The study concludes: “This study suggested beneficial effects of combined curcuminoids and piperine supplementation on disease severity in patients with NAFLD.”

In Sabinsa’s press release, Founder Dr. Muhammed Majeed commented: “We’re encouraged by the researchers’ conclusion that combined supplementation of C3 Complex and BioPerine may provide a safe and viable method for curtailing the progress of NAFLD.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here